Each month we host a distinguished guest to share information on specific topics important for the emerging field of psychedelic medicine. We invite questions for our speaker and discussion in the chat to facilitate professional networking in these online webinars. Everyone is invited to attend!
New Speaker Event: August 26, 2022
Integration is the name of the game with psychedelic assisted therapies – and in any enriching experience with a psychoactive medicine. In order to effectively support others in living the truths that emerge from journeys, every clinician in the field must know the landscape of the medicine that they facilitate, from their own psyche, and know how to make action oriented meaning of what one learns in these spaces.
Join Psychedelic Support on Friday August 26, 12-1 pm PT for a conversation with Lauren Taus, LCSW on HOW. Lauren engages a creative, integrative approach to anchor the good of psychedelic experiences, to encourage the active shifts and shed required to make meaningful changes aligned with the highest good for each individual on the path to more freedom, aliveness and joy.
Missed the live 1-hour event?
No problem! Check out our playlist of all Speaker Interviews:
2022 Series Schedule
Clinical trials of MDMA- and psilocybin-assisted therapy are investigating these as novel treatments. Ketamine is currently prescribed. As we anticipate the future of psychedelic medicine, how will clinicians decide what is the best and safest treatment for their patient?
Watch a talk around the future of psychedelic medicine in clinical practice with board-certified psychiatrist, health tech entrepreneur, and inventor, Dr. Dave Rabin, MD, PhD. He shares what’s known for safety and effectiveness for patients when it comes to utilizing ketamine, MDMA, and psilocybin. Learn about the effects and safety, screening practices, and how to evaluate risk factors.
Novel ideas for psychedelic policy reform that were once mere concepts are rapidly becoming more tangible and concrete, and are starting to be introduced and implemented in cities and states across the country. What is the difference between these approaches, and is any one path to psychedelic policy better than the others? Can the approaches to policy reform be harmonized and if so, how? Evidence nor the scientific literature support this.
Watch a practical and dynamic conversation with MAPS Director of Policy & Advocacy, Ismail Lourido Ali, JD. Hear about the landscape of the national psychedelic reform ecosystem and frameworks for analysis and engagement that play an important role in the future of psychedelic medicine.
Common practice is to tell patients on SSRIs and other prescription drugs that they must stop taking their psychiatric medications before they can safely take psilocybin, but neither anecdotal evidence nor the scientific literature support this.
Watch a presentation with integrative mental health professional and psychedelic facilitator, Dr. Erica Zelfand. She details the interplay between antidepressant medication and psilocybin.
Casting a net in the fast-paced landscape of psychedelics calls for clinicians to better understand the ways in which systematic business planning can create sustainable clinics and centers for decades to come.
Join for a discussion with physician and psychedelic industry expert Dr. Rae St. Arnault. We’ll explore areas of strategy and expertise needed for clinicians to build strong community-based psychedelic and ketamine clinics.
Balancing treatment protocols, equitable access, and regulatory compliance is a primary focus for the MAPS PBC as they look towards prescription status of MDMA in 2023.
Join MAPS PBC Chief of Patient Access and Head of Commercialization, Joy Sun Cooper, MBA and Chief of Staff, James Acer, BA for a presentation on balancing treatment protocols, equitable access, and regulatory compliance is a primary focus for MAPS PBC as they look towards prescription status of MDMA. We look at the road ahead and how MDMA-assisted therapy will available for healthcare providers, patients, and our healthcare system in future.
Join Psychedelic Support for an important discussion with bioethicist and Joseph Holcomb Adams, MA. We’ll explore how the four principles of clinical ethics (beneficence, non-maleficence, respect for autonomy, and justice) place specific ethical obligations on healthcare professionals who practice psychedelic-assisted psychotherapy.
2021 Series Schedule
Join Psychedelic.Support and Kerry Moran, MA, LPC for an important conversation about supporting clients after their ayahuasca ceremony. Integration is crucial to helping clients incorporate their unique experiences into the entire journey of their lives. Kerry offers expertise in maximizing the impact of integration work, sitting with clients in the shadow, and facilitating connection across cultures when working with ayahuasca.
Kerry Moran, MA, LPC is a graduate of the Counseling Psychology program at Pacifica University. Since she has worked in private practice as a present-centered psychotherapist, blending the wisdom of depth psychology (Jung, Hillman) with the nondual teaching of Tibetan Buddhism and mediation.
Join us as Carmen Ostrander, MA, RTC, MACA incorporates a framework for therapeutic conversations informed by Narrative Therapy with expressive arts practices, to reauthor stuck narratives and invite non-verbal ways of engaging with charged conscious and unconscious material.
The low dose end of the psychedelic spectrum provides a wealth of opportunities for clients and their therapists to collaborate creatively on the solving of problems. Low dose experiences create relational and psychological safety and confidence, encouraging novel approaches, perspectives and skill building as a foundation for more challenging psychedelic experiences clients may seek in other contexts.
Carmen Ostrander, MA, RTC, MACA is a Narrative and Expressive Arts therapist and supervisor based in Vancouver, British Columbia (Coast Salish Territories). Her independent practice, Square Peg Therapy, supports artists, queer and gender diverse folks with low barrier community centred support.
Want to dive deeper into the multidisciplinary nature of psychedelic-assisted therapy? Join us for a conversation as Andrew Penn, NP draws the parallels between the field of nursing, patient care, and top notch psychedelic integration.
Andrew Penn, NP is board certified as an adult nurse practitioner and psychiatric nurse practitioner, trained at the University of California, San Francisco. His extensive training in Psychedelic Assisted Psychotherapy at the California Institute for Integral Studies led him to be a voice for nurses in psychedelic therapy.
Andrew is a cofounder of OPENurses, a professional organization for nurses interested in psychedelic research and practice. Andrew is also a study therapist in the MAPS sponsored Phase 3 study of MDMA-assisted psychotherapy for PTSD and the Phase 2 Usona sponsored study of psilocybin facilitated therapy for major depression.
Kile Ortigo, PhD is the founder of the Center for Existential Exploration where his work is work is driven by exploring personal values, spirituality, underlying emotions, and recovery from painful life experiences. A research-trained clinician, Dr. Ortigo’s expertise in personality, attachment, trauma, and care delivery models of psychotherapy have led him to a career of advancing therapeutic protocols and manuals for clinical care, and personal growth through integrating evidence-based approaches with technology for the National Center for PTSD. Dr. Ortigo additionally serves as the Lead Editor and Consultant for Psychedelic.Support. His psychedelic work is informed by of the ineffable, the cosmos, the experience of awe, the nature of reality, and symbolism which has culminated in his newest book Beyond The Narrow Life: A Guide for Psychedelic Integration and Existential Exploration.
Chelsea Rose Pires, MA, LMFT and Sara Gael, MA, LPCC have over 17 collective years of harm reduction and peer support expertise withMAPS Zendo Project. Chelsea, a CIIS Counseling Psychology graduate has a passion for harm reduction as a therapeutic and practical approach to drug use and abuse prevention while Sara, a Naropa University graduate, served as the Director of Harm Reduction at MAPS from 2016-2020 and serves as a therapist for MAPS MDMA-assisted therapy clinical trials. Harm reduction experts, Chelsea and Sara both serve DanceSafe and their local communities by offering harm reduction support and education. Join them as they discuss the implications of psychedelic harm reduction and peer support on mental health in a clinical state.
Dr. Beatriz Caiuby Labate (Bia Labate) is a queer Brazilian anthropologist based in San Francisco. She has a Ph.D. in social anthropology from the State University of Campinas (UNICAMP), Brazil. Her main areas of interest are the study of plant medicines, drug policy, shamanism, ritual, religion and social justice. She is Executive Director of the Chacruna Institute for Psychedelic Plant Medicines. She is Public Education and Culture Specialist at the Multidisciplinary Association for Psychedelic Studies (MAPS), and Adjunct Faculty at the East-West Psychology Program at the California Institute of Integral Studies (CIIS). She is also co-founder of the Interdisciplinary Group for Psychoactive Studies (NEIP) in Brazil. She is author, co-author, and co-editor of twenty-two books, two special-edition journals, and several peer-reviewed articles.
Joshua White is Fireside Project’s Founder and Director, the first ever peer-to-peer psychedelic hotline. With experience serving as a crisis counselor on a helpline and a psychedelic peer support volunteer at the Zendo Project, Joshua has seen firsthand the role that compassionate peer support can play in community mental health. Join him for Answering The Call: Peer Support in the Psychedelic Renaissance where he’ll discuss the landscape of supporting those having difficult psychedelic experiences in a modern and technological way.
Wesley Ryan, MD discusses Clinical Applications of Ketamine-assisted Psychotherapy Treatment. A board certified addiction psychiatrist, Dr. Ryan works as a clinician providing ketamine-assisted psychotherapy to patients with depression and PTSD. He’ll share with us the integration of behavioral and insight-oriented psychospiritual work with the psychedelic properties of ketamine.
Sara Reed, LMFT and CEO of Mind’s iHealth Solutions, a digital health company that provides evidence based and culturally responsible mental health services for underserved groups. A former study therapist on the Psilocybin-Assisted Therapy research study for Major Depression at Yale University, sub-investigator and study coordinator for the Multidisciplinary Association for Psychedelic Studies (MAPS) Phase 2 MDMA study of posttraumatic stress disorder (PTSD), and member of Chacruna’s Racial Equity and Access Committee, Sara is well versed in in the implications of psychedelic research from a multicultural perspective. Join her for an important conversation about Cultural Considerations in Psychedelic Research.
Plant Medicine Law Group, a group of women lawyers who have crossed the threshold into psychedelic law. Join them in a discussion of Emerging Legal Questions for Clinicians to learn about the landscape of psychedelic law, upcoming changes and what that means for mental health care professionals who are currently practicing psychedelic integration or hope to provide psychedelic-assisted therapy in the future.
2020 Series Schedule
Jessica Nielson, PhD, founder of The Psychedelic Society of Minnesota and Assistant Profesor at the University of Minnesotadiscusses her 10-year journey towards becoming a professional psychedelic researcher within an academic setting. In My Journey: Starting Novel Psychedelic Research at a University, Dr. Nielson discusses the challenges of navigating the terrain of psychedelic research in academia, the ethical implications of white researchers performing clinical research on indigenous plant medicines, and her thoughts on the future of psychedelic studies during the COVID pandemic.
The esteemed James Fadiman, PhD, is the foremost expert on microdosing best known for his large body of psychedelic research and classic psychedelic literature such as The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys. His latest endeavor with Dr. Jordan Gruber, Your Symphony of Selves: Discover and Understand More of Who We Are explores the concept of personality multiplicity and the ability to work with different selves in various situations. Join him for Microdosing Research: The Next Frontier for Clinical Trials and Therapeutics, a conversation that examines the changing landscape of microdosing research, clinical trials, and their place in therapeutic work.
Erica Siegal, LCSW is a professional harm reductionist, community organizer, MDMA-assisted psychotherapy researcher, and founder of NEST Harm Reduction. From her years coordinating the Zendo Project, she provides an experienced look at what it means to provide compassionate, trauma-informed care and tools for de-escalation during a crisis in her talk Psychedelic Harm Reduction: What Every Clinician Needs to Know.